EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$20.94 USD
-0.90 (-4.12%)
Updated Apr 17, 2024 04:00 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EYPT 20.94 -0.90(-4.12%)
Will EYPT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EYPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EYPT
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
EYPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going
Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice
Other News for EYPT
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint reports inducement grants under Nasdaq listing rule
Strong Buy Rating for EyePoint Pharmaceuticals Amid Promising Developments in Ophthalmic Therapies
EyePoint should be bought on recent weakness, says Mizuho
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists